Inhibikase Therapeutics Inc (NAS:IKT)
$ 3.05 -0.01 (-0.33%) Market Cap: 204.94 Mil Enterprise Value: 202.51 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 37/100

Inhibikase Therapeutics Inc at ASENT Neurotherapeutics Conference (Virtual) Transcript

Feb 25, 2021 / 03:35PM GMT
Release Date Price: $42.54 (-3.01%)
Milton Werner
Inhibikase Therapeutics, Inc. - President & CEO

Well, I want to thank the organizers of ASENT for inviting Inhibikase to present some of its work related to its therapeutics and development to halt and reverse the effects of neurodegeneration and Parkinson's disease.

Just because we are a public company, I need to display this disclaimer. I'll make forward-looking statements and respective statements about our research programs. But I refer everyone that may be interested to evaluate the underlying basis of the statements in our public filings with the Securities and Exchange Commission.

So if we were to look at the way Inhibikase has gone about understanding Parkinson's disease, what we believe I will show evidence for today, is how we are going to drive functional, reversible disease in living patients. While we have a multi-therapeutic pipeline and neurodegeneration oncology in infectious disease, it really sits on the cutting edge of that science.

And the way we've been able to evaluate that cutting edge and work in both basic research and in translation

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot